ClinicalTrials.gg

Program

TE-8105

A development code. Also written as “TE-8105 MAD Cohort 1”, “TE-8105 MAD Cohort 2” and “TE-8105 MAD Cohort 3”.

Its studies are mostly in Obesity, led by Immunwork.

Furthest: phase 2, since Jun 6, 20242 company-led studies, 1 open or runningNext primary completion: Feb 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Immunwork21 open or runningphase 2since Jun 6, 2024Jun 6, 2024Feb 2028phase 2 · NCT07857473

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 6, 2024First study: phase 2 study in OverweightFirst studyNCT06471530 · 38 enrolled · Australia
  2. Sep 24, 2026Phase 2 study in OverweightNCT07857473 · 204 planned · Australia

Ahead

  1. Feb 2028Primary completion: phase 2 study in OverweightNCT07857473

TargetBeta

GLP1R →read by rule
“TE-8105 is an injectable glucagon-like peptide-1 (GLP-1) receptor agonist designed to help manage body weight and blood sugar levels.”study text, by rule · the study

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
SemaglutideruleNovo Nordiskphase 4170
LiraglutideruleNovo Nordiskphase 4116
TirzepatideruleEli Lillyphase 472
dulaglutideruleEli Lillyphase 447
orforglipronruleEli Lillyphase 350
survodutideBoehringer Ingelheimphase 335
zenagamtideNovo Nordiskphase 335
retatrutideruleEli Lillyphase 333
mazdutideruleInnovent Biologicsphase 327
bofanglutideruleGan & Lee Pharmaceuticalsphase 325
berobenatidePfizerphase 323
SafiglipronJiangsu HengRui Medicinephase 319

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07857473Overweight · Australia2Not yet recruitingFeb 2028204
NCT06471530Overweight · Australia2CompletedJan 3, 202538

How it is read

Names in the registry

  • “TE-8105 MAD Cohort 1”, 2 entries
  • “TE-8105 MAD Cohort 2”, 2 entries
  • “TE-8105 MAD Cohort 3”, 1 entry
  • “TE-8105 SAD Cohort 1”, 1 entry
  • “TE-8105 SAD Cohort 3”, 1 entry

Codes read as this program: TE8105.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.